Earlier today, TNI BioTech, a biotech company focused on utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, announced that Umbrella Research is now covering the company with a “buy” rating and $26 price target.
The entire 33-page report has been posted on the company’s Web site at http://www.tnibiotech.com/investor-relations/reports
The following is an excerpt of the report: “It is our opinion that TNI presents investors with significant upside from current prices based on a two-fold growth strategy including: the near term commercialization of its existing immunotherapies targeting cancer and HIV/AIDS; coupled with the potential contribution from the phase 3 study of low dose naltrexone (LDN) for use in Crohn’s disease, scheduled to begin in 2014. As the company enters 2013 it should be in a position where ramping revenue run rates not only allow it to be self-funding in regard to clinical development costs, but also for this to translate quickly into an earnings driven growth story for investors with significant potential upside from approvals.”
For more information on the company and its immunotherapies, visit www.tnibiotech.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The QualityStocks Daily Blog http://blog.qualitystocks.net
The QualityStocks Video Charts http://videocharts.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment